细胞因子诱导杀伤细胞免疫治疗在肾细胞癌治疗中的效果及价值  

Effect and Value of Cytokine-induced Killer Cell Immunotherapy in the Treatment of Renal Cell Carcinoma

作　　者：刘晓光[1] LIU Xiaoguang(Henan Provincial Hospital of Traditional Chinese Medicine,Zhengzhou,450002)

机构地区：[1]河南省中医院,450002

出　　处：《实用癌症杂志》2023年第1期95-97,共3页The Practical Journal of Cancer

摘　　要：目的 探讨细胞因子诱导杀伤细胞(CIK)免疫治疗在肾细胞癌(RCC)治疗中的效果及价值。方法 选择RCC患者108例,采用随机数字表法分为两组,各54例。对照组术后行白细胞介素-2(IL-2)治疗,观察组予以CIK治疗,持续4个疗程。比较两组外周血象及肝肾功能、免疫功能[CD_(3)^(+)、CD_(4)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+)、自然杀伤细胞(NK)、CD_(4)^(+)CD_(25)^(+)T细胞]。结果 2组治疗前、后外周血象及肝肾功能比较,差异无统计学意义(P>0.05);2组治疗前免疫功能指标比较,差异无统计学意义(P>0.05);观察组治疗后CD_(8)^(+)、CD_(4)^(+) CD_(25)^(+)水平均低于对照组,CCD_(3)^(+)、CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)、NK水平均高于对照组,差异有统计学意义(P<0.05)。结论 在RCC患者中采用CIK治疗效果确切,利于调节免疫功能,且不会对患者外周血象及肝肾功能造成影响,是一种安全有效的治疗方案。另外,治疗过程需加强对患者的健康教育,向患者普及疾病、治疗相关知识,提高患者治疗依从性。Objective To investigate the effect and value of cytokine-induced killer cell(CIK) immunotherapy in the treatment of renal cell carcinoma(RCC).Methods 108 RCC patients were selected and divided into 2 groups using random number table method with 54 each.The control group was treated with interleukin-2(IL-2) after surgery, and the observation group was treated with CIK for 4 courses.The 2 groups were compared for peripheral blood images and liver and kidney function, immune function [CD_(3)^(+),CD_(4)^(+),CD_(8)^(+),CD_(4)^(+)/CD_(8)^(+),natural killer cells(NK),CD_(4)^(+)CD_(25)^(+)T cells].Results No(P>0.05);the immune function indicators before treatment(P>0.05);CD_(8)^(+)and CD_(4)^(+)CD_(25)^(+)were lower than the control group, and the levels of CD_(3)^(+),CD_(4)^(+),CD_(4)^(+)/CD_(8)^(+)and NK were higher than the control group(P<0.05).Conclusion CIK in RCC patients is effective to regulating immune function, and does not affect peripheral blood image and liver and kidney function.It is a safe and effective treatment plan.In addition, the treatment process needs to strengthen the health education of patients, popularize the relevant knowledge of disease and treatment to patients, and improve the treatment compliance of patients.

关 键 词：肾细胞癌 细胞因子诱导杀伤细胞 免疫治疗 免疫功能 

分 类 号：R737.11[医药卫生—肿瘤]